Skip to main content

Table 2 Post-Ipi Systemic Txs.

From: Patterns of long-term survival following Ipilimumab (Ipi): the Memorial Sloan Kettering Cancer Center 10-year metastatic melanoma (MM) experience

Post-Ipi

Systemic Tx

# pts

# pts achieving ≥1yr disease control*

Cytotoxic Therapy

11/80 (14%)

5/10 (50%)

Anti-PD-1/PD-L1

16/80 (20%)

11/15 (73%)

BRAF inhibitor

10/80 (13%)

7/9 (78%)

Ipi re-induction

18/80 (23%)

5/16 (31%)

Other clinical trial

13/80 (16%)

1/13 (8%)

  1. *pts with ongoing disease control and <1yr follow up excluded